Cargando…

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

The therapeutic options available for patients with multiple myeloma have greatly expanded over the past decade and incorporating these novel agents into routine clinical practice has significantly improved outcomes. The next generation of therapeutics is available for relapsed and refractory patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinbach, Mary, Julian, Kelley, McClune, Brian, Sborov, Douglas W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289924/ https://www.ncbi.nlm.nih.gov/pubmed/35860442 http://dx.doi.org/10.1177/20406207221100659

Ejemplares similares

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

Financial toxicity in hematological malignancies: a systematic review
por: Ouchveridze, Evguenia, et al.
Publicado: (2022)

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
por: Bolli, Niccolo, et al.
Publicado: (2020)

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
por: Griffin, Rosalie, et al.
Publicado: (2023)

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
por: Balmaceda, Nicole, et al.
Publicado: (2021)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Multiple Myeloma: Risk Stratification and Toxicity Management
por: Richards, Tiffany, et al.
Publicado: (2018)

Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population
por: Barth, Dylan, et al.
Publicado: (2022)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Differential loss of components of traditional ecological knowledge following a primate extinction event
por: Turvey, Samuel T., et al.
Publicado: (2018)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Next-Generation Technologies and Strategies for the Management of Retinoblastoma
por: Gudiseva, Harini V., et al.
Publicado: (2019)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

LIVING WITH MULTIPLE MYELOMA: SELF-MANAGEMENT STRATEGIES
por: LeBlanc, Matthew R, et al.
Publicado: (2019)

A Focus on Special Populations in Relapsed Multiple Myeloma
por: Steinbach, Mary, et al.
Publicado: (2022)

Engineering Next-Generation CAR-T Cells for Better Toxicity Management
por: Andrea, Alain E., et al.
Publicado: (2020)

Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2022)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
por: Yu, Shengnan, et al.
Publicado: (2019)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis
por: Soliman, Amro M., et al.
Publicado: (2021)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Fair data for next-generation management of multiple sclerosis
por: Peeters, Liesbet M
Publicado: (2017)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Engineering orthogonal signaling pathways reveals the sparse occupancy of sequence space
por: McClune, Conor J., et al.
Publicado: (2019)

BEAM Conditioning Is Well Tolerated and Yields Similar Survival in Obese and Non-Obese Patients with Lymphoma: No Requirement for Weight-Based Dose Modifications
por: Fair, Christina, et al.
Publicado: (2017)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
por: Rasche, Leo, et al.
Publicado: (2019)

Therapeutic strategies to enhance immune response induced by multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i49eqoddtcvh0f48f6dk37p6rm